BUSINESS WIRE: New technology is changing way of treatment of … – Finanztreff

RELEASE UEBERMITTELT VON BUSINESS WIRE. FOR THE CONTENT IS SOLELY THE REPORTING COMPANY RESPONSIBLE.

ST. PAUL (Minnesota, USA) – (BUSINESS WIRE) – 01.07.2014 –

thorax Medical announced today the release of new data from two leading U.S. hospitals are known by which the safety and efficacy of LINX Reflux Treatment system for patients with reflux esophagitis (Gastroesophageal Reflux Disease; GERD) is further evidenced suffer

A chronic reflux esophagitis, if you do not quite responsive to medical treatment, lead to serious complications. inter alia, to precancerous Barrett’s esophagus and esophageal cancer. The symptoms are often debilitating, as daily pain, difficulty swallowing, and trouble sleeping may belong. The disease may also be problems with upper respiratory tract, such as asthma and bronchitis / pneumonia, may be connected. The commonly prescribed to treat symptoms of gastroesophageal reflux disease medical treatment (for acid suppression drugs) do not fix the actual cause of the disease, in a weak sphincter (valve) between the stomach and esophagus.

C. Daniel Smith, MD, professor of surgery at the Mayo Clinic Jacksonville (Florida), recently published his experience with the magnetic Schließmuskelaugmentationssystem LINX Journal of the American College of Surgeons . “Our clinical experience with the LINX system fit to the observations that have been made in controlled trials. It is important that we look at LINX as a new treatment option for patients who suffer permanent, despite taking medication at reflux esophagitis. The opportunity to offer patients a minimally invasive treatment, with her esophagus sphincter is restored without major side effects, has long been a clinical need, the LINX apparently can meet, “said Dr. Smith.

In a second study which was recently published in the Annals of Thoracic Surgery , are results with LINX by Brian Louie, MD, chief thoracic research and education, with colleagues from the Swedish Cancer Institute and Medical Center in Seattle (Washington) presented. The team examined the Schließmuskelaugmentation with LINX and case-specific sphincter reconstructions for which the gastric fundus of the patient was used (Nissen fundoplication). The study results showed that both LINX and fundoplication brought significant improvements of symptoms of reflux, such as heartburn, reflux (regurgitation) and cough with it. Patients who LINX got used, it fell after the procedure, however, push open easily, and they had less bloating and less often the feeling of a bloated abdomen -. Symptoms that are usually associated with a laparoscopic Nissen fundoplication surgery

“The LINX device seems to restore the sphincter barrier function and maintain normal physiology, belching and vomiting enables,” said Dr. Brian Louie. “LINX is a significant new surgical treatment option for patients in whom medical treatment does not strike and the worsening of reflux esophagitis to suffer.”

The LINX device is tested in clinical trials for more than seven years. With these studies, the documents are augmented and substantiated that the LINX System is an effective and medically necessary treatment manner within the range of treatments for patients who suffer from reflux esophagitis.

disease

The reflux esophagitis (Gastroesophageal Reflux Disease, or GERD) is a chronic, often progressive disease that is due to a weak lower esophageal sphincter, making reflux harmful gastric juices occurs in the esophagus, which leads to both pain as well as lesions in the lining of the esophagus. The symptoms of GERD are heartburn and vomiting, often accompanied by chronic sleep disruption. The disease can also persistent cough, excessive throat clearing, hoarseness, and a feeling of having a “lump” in the throat cause. Acid blockers such as Prevacid ® ® , Nexium ® and Prilosec ® inhibit the production of stomach acid, but do not eliminate the defect in the sphincter of the esophagus, causing recurrent reflux allows will. GERD is a precancerous condition known as Barrett’s esophagus, associated, which increases the risk of esophageal cancer.

The LINX Reflux Management System

LINX is a small implant, which consists of interconnected titanium beads with magnetic cores. The magnetic attraction between the beads increases the existing sphincter muscle force of the esophagus, thereby preventing the reflux. The device is implanted by means of a minimally invasive laparoscopic procedure and standard provides an alternative to more anatomically engaging fundoplication, which is usually used as a surgical method for reflux control. The LINX ® ® Reflux Management System is indicated for patients having demonstrated on the basis of abnormal pH values ​​a reflux esophagitis (GERD) is diagnosed, and still suffering from chronic GERD symptoms, although the maximum medical therapy have received for the treatment of gastroesophageal reflux.

LINX requires a surgical procedure and is associated with potential risks, contraindications and lifestyle changes. For more information about LINX, including a brief description of the risks, see www.linxforlife.com.

thorax Medical

thorax Medical Inc. a private medical device company headquartered in St. Paul, Minnesota. Thorax Medical Inc. develops and markets products to treat sphincter disorders using its technology platform, Magnetic Sphincter Augmentation (MSA). Thorax Medical currently marketed both the LINX ® Reflux Management System for the treatment of GERD in the U.S. and Europe as well as the FENIX ™ Continence Restoration System for the treatment of fecal incontinence in Europe. For more detailed information, please visit www.toraxmedical.com.

The source language of the original text of this announcement is the official, authoritative version. Translations are provided as an accommodation. Only the language version that was published in the original, is quite valid. Therefore Straighten translations with the original language of publication from.

thorax Medical, Inc.
Maggie Wallner, 651-361-8900
mwallner@toraxmedical.com